文献速递腹部儿科影像MR

生物制剂治疗新诊断回肠型克罗恩病儿童与青年肠道动力的MRI特征:对照前瞻性研究

MRI-Based Characterization of Intestinal Motility in Children and Young Adults With Newly Diagnosed Ileal Crohn Disease Treated by Biologic Therapy: A Controlled Prospective Study.
PubMed 文献 · AJR Am J Roentgenol · 2022-05-11

前瞻性纳入20例新诊断回肠型克罗恩病儿童与青年及15名无胃肠道疾病对照,采用动态电影2D SSFP序列MRI评估终末回肠肠道动力评分。患者组与对照组基线动力评分无显著差异,生物制剂治疗后6周和6个月动力评分较基线升高;两名操作者间绝对一致性ICC=0.89。

要点

  • 动态电影2D SSFP序列可定量终末回肠肠道动力,两名操作者间ICC=0.89。
  • 新诊断回肠型克罗恩病与对照基线动力评分无显著差异。
  • 生物制剂治疗后6周和6个月动力评分较基线升高。

核心结论

  • MRI测量的肠道动力在新诊断小肠克罗恩病儿童和成人中呈动态变化,生物制剂治疗后早期升高。

研究设计与样本

  • 前瞻性对照研究,纳入20例新诊断回肠型克罗恩病儿童与青年(8例女性、12例男性,平均年龄14.6±2.1岁)及15名无已知胃肠道疾病对照(8例女性、7例男性,平均年龄18.1±4.4岁),患者于2018年12月至2021年10月招募,均行小肠研究性MRI含动态电影2D SSFP序列,患者于生物制剂启动后6周和6个月复查。

关键影像表现/征象

  • 肠道动力评分由动态电影序列经FDA批准软件导出,评分越高表示肠道动力越大。
  • 新诊断回肠型克罗恩病患者与对照的平均终末回肠肠道动力评分无显著差异。

诊断标准与关键数值

  • 操作者1:患者基线180.9±63.3 vs 对照229.7±115.2,p=.12。
  • 操作者2:患者基线175.0±62.2 vs 对照236.4±117.4,p=.05。
  • 操作者1:基线180.9±63.3、治疗启动后6周248.1±104.9、6个月249.1±73.2,p=.04。
  • 操作者2:基线175.0±62.2、治疗启动后6周247.8±112.7、6个月239.6±72.7,p=.03。
  • 两名操作者间肠道动力评分绝对一致性ICC=0.89。

临床应用与阅片要点

  • 动态电影2D SSFP序列可用于定量终末回肠肠道动力评分,操作者间一致性高。
  • MRI肠道动力评分可能有助于小肠克罗恩病患者疾病活动度和治疗反应的个体化评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Changes in intestinal motility in patients with newly diagnosed Crohn disease have historically been evaluated primarily in a subjective manner. OBJECTIVE. The purpose of this study was to assess longitudinal changes in objective intestinal motility scores in children and young adults with newly diagnosed ileal Crohn disease treated with biologic (anti-tumor necrosis factor-α) medical therapy compared with those in control participants. METHODS. This prospective study included 20 children and young adults (eight female and 12 male patients; mean age, 14.6 ± 2.1 [SD] years) with newly diagnosed ileal Crohn disease who were recruited between December 2018 and October 2021 as well as 15 control participants without any known gastrointestinal conditions (eight female and seven male patients; mean age, 18.1 ± 4.4 years). All participants underwent research MRI examinations of the small bowel, including dynamic cine 2D SSFP sequences. Patients with Crohn disease underwent additional research MRI examinations performed at both 6 weeks and 6 months after initiation of biologic therapy. Two operators independently derived terminal ileal intestinal motility scores from the dynamic cine sequences by use of FDA-approved software (with higher scores indicating greater intestinal motility). Intestinal motility scores were compared between patient and control groups by use of t tests, whereas changes in intestinal motility scores after treatment were assessed using linear mixed models. Interoperator absolute agreement was assessed using the intra-class correlation coefficient (ICC). RESULTS. Mean terminal ileal intestinal motility scores were not significantly different between patients with newly diagnosed ileal Crohn disease and control participants (for operator 1, 180.9 ± 63.3 vs 229.7 ± 115.2, respectively [p = .12]; for operator 2, 175.0 ± 62.2 vs 236.4 ± 117.4, respectively [p = .05]). Mean intestinal motility scores changed over time compared with baseline in response to biologic therapy, for operator 1 (180.9 ± 63.3 at baseline, 248.1 ± 104.9 at 6 weeks after treatment initiation, and 249.1 ± 73.2 at 6 months after treatment initiation [p = .04]) and operator 2 (175.0 ± 62.2 at baseline, 247.8 ± 112.7 at 6 weeks after treatment initiation, and 239.6 ± 72.7 at 6 months after treatment initiation [p = .03]). Absolute agreement in intestinal motility scores was excellent between operators (ICC = 0.89). CONCLUSION. MRI measurements of intestinal motility are dynamic in children and adults with newly diagnosed small-bowel Crohn disease, showing early increases in response to biologic therapy. CLINICAL IMPACT. MRI-based intestinal motility scores may aid individualized assessment of disease activity and treatment response in patients with small-bowel Crohn disease.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Dillman, Tkach, Imbus, et al. MRI-Based Characterization of Intestinal Motility in Children and Young Adults With Newly Diagnosed Ileal Crohn Disease Treated by Biologic Therapy: A Controlled Prospective Study. AJR Am J Roentgenol. 2022. PMID: 35544371. doi:10.2214/AJR.22.27792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。